8/24/2007

GlaxoSmithKline has requested preliminary study results from Exelixis for the experimental cancer drug XL880. Exelixis could receive a $70 million milestone payment if GSK continues to develop the drug, one analyst said.

Full Story:
Bloomberg

Related Summaries